Drug news
Cariprazine filed at EMA for treatment of schizophrenia.- Gedeon Richter
Gedeon Richter Plc. announced that the European Medicines Agency (EMA) has accepted Richter's regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. Cariprazine was discovered by Richter scientists and is licensed to Allergan (earlier Forest / Actavis), in the U.S. and Canada. Following its FDA approval in September 2015, the product has been recently launched in the USA under the trademark of Vrayler for the treatment of both schizophrenia and bipolar mania.